New study tracks sorafenib safety in Hard-to-Treat thyroid cancer
NCT ID NCT02185560
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study monitors 453 patients with advanced thyroid cancer that cannot be removed by surgery and does not respond to radioactive iodine. All patients are taking the drug sorafenib (Nexavar) as part of their normal care. Researchers are tracking side effects and how long patients live or stay on treatment over 9 to 24 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sorafenib (Nexavar)
- What this could lead to
- If successful, this study will confirm the safety and real-world effectiveness of sorafenib for advanced thyroid cancer, supporting its continued use.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by short follow-up and lack of a comparison group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Drug duo aims to starve thyroid tumors
- Could drug holidays improve thyroid cancer treatment?
- New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
- New ultrasound method may cut unnecessary thyroid biopsies
- Tiny scope, big difference? study tests Microscope-Assisted thyroid surgery
- Childhood radiation linked to thyroid cancer? new study aims to find out